The study investigated the efficacy of Qingke Pingchuan Granules (QKPC) as an adjunctive treatment in acute exacerbation of chronic obstructive pulmonary disease, acute exacerbation of asthma and acute bronchitis. 21 randomized controlled trials with a total of 2087 participants were included in the analysis. The results showed that QKPC combined with conventional treatment significantly improved clinical outcomes including overall response rate, lung function (FEV₁% and FVC) and reduced inflammatory markers such as CRP. CAT scores, mMRC scores, 6-minute walk distance, and blood oxygen level (PaO₂) also improved in patients with COPD exacerbations. The incidence of adverse events was not significantly different between the QKPC group and the control group, and no liver or kidney function abnormalities were observed. The researchers concluded that QKPC represents a safe and effective adjunctive therapy for these acute inflammatory airway diseases.